TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Galmed Pharmaceuticals ( (GLMD) ) has shared an update.
On December 4, 2025, Galmed Pharmaceuticals announced the grant of a new use patent in South Korea for a combination therapy involving its lead compound, Aramchol, and Madrigal Pharmaceuticals’ Rezdiffra (Resmetirom) for treating non-alcoholic steatohepatitis (MASH) and liver fibrosis. This patent, which extends Aramchol’s protection worldwide until July 2042, marks a significant step in the company’s strategy to lead in the NASH/MASH combination therapy market. The announcement underscores the industry’s shift towards combination therapies to address complex diseases like MASH, highlighting Aramchol’s excellent safety and tolerability as a key advantage.
Spark’s Take on GLMD Stock
According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.
Galmed Pharmaceuticals faces significant financial challenges, with no revenue and continuous losses, which heavily impact its stock score. Poor technical indicators and negative valuation metrics further weigh down the score. The strong equity position offers some support but is overshadowed by the lack of operational efficiency and profitability.
To see Spark’s full report on GLMD stock, click here.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for liver, cardiometabolic diseases, and gastrointestinal oncological therapeutics. The company is primarily dedicated to advancing its lead compound, Aramchol, for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis, while also exploring its potential for oncological indications and other cardiometabolic conditions.
Average Trading Volume: 2,046,492
Technical Sentiment Signal: Sell
Current Market Cap: $5.25M
For a thorough assessment of GLMD stock, go to TipRanks’ Stock Analysis page.